Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is investigating reports that more patients are experiencing serious bleeding events after taking Boehringer Ingelheim GmbH’s Pradaxa (dabigatran) than anticipated based on clinical trial results.


Related Content

Pradaxa Bleeding Events Prompt FDA To Revise Generic Bioequivalence Criteria
FDA’s Pradaxa Review Overemphasized Efficacy, Safety Experts Argue
BMJ’s Pradaxa Exposé Includes Wider Call For Monitoring Of All New Anticoagulants
Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement
BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval
Xarelto Approval For DVT Bodes Well For Coming Indications
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts